ITGBL1 Antibody (Center) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | O95965 |
---|---|
Clone Names | 91023181 |
Gene ID | 9358 |
---|---|
Other Names | Integrin beta-like protein 1, Osteoblast-specific cysteine-rich protein, Ten integrin EGF-like repeat domain-containing protein, ITGBL1, OSCP, TIED |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP8781c was selected from the Center region of human ITGBL1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | ITGBL1 |
---|---|
Synonyms | OSCP, TIED |
Cellular Location | Secreted. |
Tissue Location | Widely expressed in many tissues, but readily detectable only in aorta. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Osteoblast specific cysteine-rich protein (OSCP) is integrin, 锟?like 1 (with EGF-like repeat domains).
References
Berg R.W., et.al., Genomics 56:169-178(1999).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.